COMPOUNDS FOR TREATMENT OF HYPOPROLIFERATIVE DISORDERS
申请人:LU LICENSE AB
公开号:US20190111034A1
公开(公告)日:2019-04-18
The present invention relates to the use of CDK8 and/or CDK19 inhibitors in the treatment of ribosomopathies as well as conditions characterized by reduced number of hematopoietic stem cells and/or progenitor cells; and bone anabolic disorders.
[EN] COMPOUNDS FOR TREATMENT OF HYPOPROLIFERATIVE DISORDERS<br/>[FR] COMPOSÉS DESTINÉS AU TRAITEMENT DE DÉSORDRES HYPERPROLIFÉRATIFS
申请人:LU LICENSE AB
公开号:WO2017076968A1
公开(公告)日:2017-05-11
The present invention relates to the use of CDK8 and/or CDK19 inhibitors in the treatment of ribosomopathies as well as conditions characterizedby reduced number of hematopoietic stem cells and/or progenitor cells; and bone anabolic disorders.